Benten Biotech
São Paulo, Brazil· Est.
A Uruguay‑based CRO delivering patented veterinary biologics and diagnostics through nanobody and recombinant vaccine platforms.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $4M
AI Company Overview
A Uruguay‑based CRO delivering patented veterinary biologics and diagnostics through nanobody and recombinant vaccine platforms.
VeterinaryImmunology
Technology Platform
Camelid heavy‑chain single‑domain antibodies (VHH) nanobodies combined with recombinant vaccine technology for veterinary diagnostics and therapeutics.
Opportunities
Expanding the nanobody platform into therapeutic veterinary indications and entering new Latin American markets can drive revenue growth.
Risk Factors
Regulatory heterogeneity across countries and competition from larger CROs could limit market penetration.
Competitive Landscape
Benten differentiates itself from traditional CROs like Charles River and Boehringer Ingelheim Animal Health through its integrated IP strategy and nanobody expertise.